Inactive Instrument

Physiomics Plc Stock London S.E.

Equities

GB00B04QT956

Professional Information Services

End-of-day quote London S.E.
- GBX - Intraday chart for Physiomics Plc
Sales 2024 * 900K 1.13M Sales 2025 * - Capitalization 1.76M 2.21M
Net income 2024 * - 0 Net income 2025 * - EV / Sales 2024 * 1.57 x
Net cash position 2024 * 349K 438K Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-4.64 x
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.74%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer - 23-09-04
Chairman 55 16-04-17
Director of Finance/CFO 50 -
Members of the board TitleAgeSince
Director/Board Member 73 22-03-31
Chief Tech/Sci/R&D Officer 54 04-04-30
Director/Board Member - 22-08-31
More insiders
Physiomics PLC is a United Kingdom-based company, which provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology. The Company offer its services by utilizing its proprietary Virtual Tumour predictive software, industry standard tools (such as NONMEM and MATLAB), as well as developing bespoke models using the R programming language. Virtual Tumour is a predictive quantitative systems' pharmacology (QSP) model used worldwide by global pharmaceuticals to small biotech companies to support oncology Research and development (R&D). It is a semi-mechanistic model that incorporates an abstracted representation of the cell cycle, Deoxyribonucleic acid (DNA) damage/ repair and elements of the immune response. The Company is also developing its technology for use in the field of personalized medicine. The Company is focused on helping pharma and biotech clients.
More about the company